THURSDAY, Sept. 27 (HealthDay News) -- Stivarga (regorafenib) has been approved by the U.S. Food and Drug Administration to treat colorectal cancer that has spread despite prior treatment.
Latest Cancer News
The drug belongs to a class called multi-kinase inhibitors, which are designed to block enzymes that promote cancer growth, the FDA said in a news release.
Stivarga's safety and effectiveness were evaluated in a clinical study of 760 people who had been treated previously for advanced colon cancer. People who took Stivarga lived an average of 6.4 months, compared with people given a placebo who lived an average of five months, the FDA said.
Stivarga was approved with a boxed label warning of the possibility of severe and fatal liver problems, the FDA said.
The drug is marketed by Bayer HealthCare Pharmaceuticals, based in Wayne, N.J.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
Subscribe to MedicineNet's Cancer Report Newsletter